Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer (Q34979517)

5 August 2017

1 reference

title

Studies using the anti-idiotypic monoclonal antibody 105AD7 in patients with primary and advanced colorectal cancer (English)

1 reference

5 August 2017

1 reference

Charles Maxwell-Armstrong

series ordinal

1

1 reference

5 August 2017

publication date

1 September 2002

1 reference

Annals of the Royal College of Surgeons of England

5 August 2017

published in

1 reference

5 August 2017

volume

84

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

314-318

1 reference

Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Immunotherapy for colorectal cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Colorectal cancer vaccines

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Surgeons' follow-up practice after resection of colorectal cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Immunological/physiological relationships in asthma: potential regulation by lung macrophages

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Immune response to the carcinoembryonic antigen in patients treated with an anti-idiotype antibody vaccine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Response of resting human peripheral blood natural killer cells to interleukin 2.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Expression of interleukin 2 receptors on activated human B cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

T-cell responses at the host: tumour interface

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Anti-idiotype immunization of cancer patients: modulation of the immune response

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

The development of new immunotherapies for the treatment of cancer using interleukin-2. A review

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

The interleukin 2 receptor

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Induction of delayed hypersensitivity to human tumor cells with a human monoclonal anti-idiotypic antibody

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Immunostimulation with intraperitoneally administered bacille Calmette Guérin for advanced malignant tumors of the gastrointestinal tract

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2504168

Characterization of activated lymphocytes in colon cancer

8 July 2018

1 reference

12 December 2020

Vaccine-induced apoptosis: a novel clinical trial end point?

1 reference

12 December 2020

Current perspectives on immunotherapy for colorectal cancer

1 reference

12 December 2020

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

12 December 2020

Elevation of infiltrating mononuclear phagocytes in human colorectal tumors

1 reference

12 December 2020

Decay accelerating factor (CD55): a target for cancer vaccines?

1 reference

12 December 2020

Enhanced cell-mediated tumor killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7

1 reference

12 December 2020

Anti-idiotype cancer vaccines: pre-clinical and clinical studies

1 reference

12 December 2020

Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 791T/36

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses

1 reference

12 December 2020

Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease

1 reference

12 December 2020

Long-term survival following levamisole or placebo adjuvant treatment of colorectal cancer: a Western Cancer Study Group Trial

1 reference

12 December 2020

Anti-idiotypic antibodies bear the internal image of a human tumor antigen

1 reference

12 December 2020

The balance of macrophage subsets may be customised at mucosal surfaces

1 reference

12 December 2020

Interleukin 2 (IL 2) up-regulates its own receptor on a subset of human unprimed peripheral blood lymphocytes and triggers their proliferation

1 reference

12 December 2020

A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55

1 reference

12 December 2020

A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone

1 reference

12 December 2020

Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody

1 reference

12 December 2020

Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody

1 reference

12 December 2020

T-cell cytokines may control the balance of functionally distinct macrophage populations

1 reference

12 December 2020

10.1308/003588402760452402

Identifiers

DOI

1 reference

5 August 2017

1 reference

5 August 2017

1 reference